Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 248 of 6351
-
Can a pill replace the CPAP machine for sleep apnea?
Disease control CompletedThis is a phase 2 randomized double-blind placebo-controlled parallel-arm dose finding study to compare fixed dose combinations of AD109 and AD504 to atomoxetine or placebo in Obstructive Sleep Apnea.
Phase 2 • Sponsor: Apnimed • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can radiation plus two immunotherapies shrink Hard-to-Treat tumors?
Disease control OngoingNivolumab (and other agents affecting the anti-programmed death-1 \[anti-PD-1\] pathway) have demonstrated anti-tumor activity in multiple tumor types. Combinations of immune-oncology (IO) agents with complimentary mechanisms as well as radiation represent a promising strategy to…
Phase 1 • Sponsor: Yana Najjar • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Could sterile water match chemotherapy in preventing bladder cancer return?
Prevention Recruiting nowThere is a high rate of intravesical (bladder) recurrence following extirpative surgery for upper tract urothelial carcinoma. There is no single established standard of care for prevention of intravesical recurrence; however, one protocol in common use involves the use of intrave…
Phase 3 • Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated Aug 19, 2026 00:00 UTC
-
Can a new pill silence the itch of chronic hives?
Disease control CompletedThe first phase of this study will be a parallel, 12-week treatment, Phase 2, double-blind, 4 arm study to assess the safety and effectiveness of 3 oral doses of SAR444671 (rilzabrutinib), i.e. dose A, B and C, compared with placebo for decreasing the frequency and severity of it…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New pill combo shows promise against resistant lung cancer
Disease control CompletedThis study will look at how effective the study drug(Savolitinib combined with Osimertinib) versus Pemetrexed combined with platinum in treatment of patients with locally advanced or metastatic NSCLC with MET amplification after failure of the first-line EGFR inhibitor therapy.
Phase 3 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo aims to keep aggressive lung cancer at bay longer
Disease control OngoingStudy GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line in…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 10, 2026 05:00 UTC
-
Could a common food preservative help treat Hard-to-Treat schizophrenia?
Disease control Recruiting nowAlthough antipsychotic is effective for schizophrenia, however, still certain proportion of patients were not responsive to treatment. Treatment resistant schizophrenia (TRS) is accompanied by function decline and heavy burden. In recent decades, the biological mechanism of schiz…
Phase 2 • Sponsor: National Cheng-Kung University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for lung cancer: targeted drug takes on chemo in Late-Stage trial
Disease control OngoingThe goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).
Phase 3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug cocktail may spare hodgkin patients from stem cell transplant
Disease control Recruiting nowThis phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal …
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Gene-Guided cancer care: new trials aim to stop endometrial cancer return
Disease control Recruiting nowThe RAINBO umbrella program consists of four clinical trials investigating new adjuvant therapies in endometrial cancer patients. Eligible patients will be assigned to one of the four RAINBO trials based on the molecular profile of their cancer: * p53 abnormal endometrial cancer…
Phase 2/3 • Sponsor: Leiden University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can a new drug combo help CML patients stop treatment for good?
Disease control Recruiting nowThis is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Tyrosine Kinase inhibitors (TKI). All patie…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Immune-Boosting drug combo takes on Hard-to-Treat ovarian cancer
Disease control OngoingThis pilot clinical trial studies the effect of pembrolizumab and lenvatinib in treating patients with high-grade serous ovarian cancers. Immunotherapy with monoclonal antibodies such as pembrolizumab may help the body's immune system attack the cancer, and may interfere with the…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a simpler brain stimulation match the gold standard for depression?
Disease control Recruiting nowThe aim of this study is to test the hypothesis that low-frequency rTMS (LFR) works as well as the established intermittent thetaburst rTMS (iTBS) treatment for treatment resistant depression (TRD).
Sponsor: University of British Columbia • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Triple therapy aims to outsmart stomach cancer
Disease control OngoingThis study is to compare and evaluate the efficacy and safety of ONO-4538 in combination with ipilimumab and chemotherapy versus chemotherapy in chemotherapy-naïve participants with HER2-negative unresectable advanced or recurrent gastric cancer (including esophagogastric junctio…
Phase 3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene therapy after stem cell transplant shows promise for rare brain disease
Disease control OngoingThis is a nonblinded, non-randomized dose escalation study of intravenous AAVrh10 after hematopoietic stem cell transplantation (HSCT) in which subjects will receive standard of care hematopoietic cell transplantation for Krabbe disease, followed by a single infusion of an adeno-…
Phase 1/2 • Sponsor: Forge Biologics, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a 3-Month TB cocktail replace the standard 6-Month regimen?
Disease control Stopped earlyThe purpose of this study was to compare a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with a CFZ loading dose with the 6-month standard of care (SOC) regimen for drug-susceptible (DS) tuberculosis (TB).
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
One dose, big hope: antibiotic may stop cholera in kids
Prevention CompletedThis study aims to determine whether single-dose azithromycin is effective in preventing cholera in children who are at extremely high risk of infection. The study will also determine the effect of this intervention on the development of antibiotic resistant bacteria. The results…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Prevention
Last updated Aug 09, 2026 00:00 UTC
-
New Dual-Targeting CAR T-Cells aim to outsmart tough lymphoma
Disease control Recruiting nowThe goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Phase 1/2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for lymphoma patients: drug duo aims to control relapsed disease
Disease control OngoingThis study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one …
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could a targeted drug boost transplant success for tough blood cancers?
Disease control Recruiting nowThis phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemotherapy drugs, such as venetoclax, busulfa…
Phase 2/3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC